138 results on '"Lübbert, A."'
Search Results
2. Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA
3. Innovative strategies for adverse karyotype acute myeloid leukemia
4. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2′-deoxycytidine (Decitabine)
5. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5‐aza‐2′‐deoxycytidine (Decitabine)
6. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
7. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
8. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
9. BF-1 – A novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs
10. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges
11. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes
12. Genetic mouse models for Parkinsonʼs disease display severe pathology in glial cell mitochondria
13. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
14. Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells
15. Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2–producing k. pneumoniae in liver transplant recipients
16. Long-term carriage of Klebsiella pneumoniae carbapenemase–2-producing K pneumoniae after a large single-center outbreak in Germany
17. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
18. Clinical development of demethylating agents in hematology
19. Monosomal karyotype in MDS: explaining the poor prognosis?
20. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
21. Batch-to-batch reproducibility of fermentation processes by robust operational design and control
22. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
23. A novel recurrent AML1-ETO fusion: tight in vivo association with BCR-ABL1
24. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis
25. Quantitative analyses of DAPK1 methylation in AML and MDS
26. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
27. Photodynamic therapy with BF–200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer–blind phase III study in comparison with a registered methyl–5–aminolaevulinate cream and placebo
28. Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia
29. Treatment of transfusional iron overload with deferasirox in patients with low and intermediate-1 risk MDS: Results from a German multi-center trial: V959
30. Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry): V954
31. Characterization and prognostic significance of cytogenetically unrelated clones in myelodysplastic syndromes and acute myeloid leukemia: V68
32. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO
33. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation
34. Therapeutic granulocyte transfusions in neutropenic patients with invasive pulmonary aspergillosis and haematological malignancies: P772
35. Allogeneic transplantation from matched related and unrelated donors in first complete remission in younger adult AML patients with FLT3 internal tandem duplications: O277
36. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
37. Loss of the Y Chromosome in MDS: Clonal abnormality or age-related accident?: V749
38. Long term follow up of elderly patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL): Updated results of the GMALL elderly trials: V709
39. Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib
40. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
41. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study
42. Upregulation of cathepsin S in psoriatic keratinocytes
43. Selective expression of the soluble product fraction in Escherichia coli cultures employed in recombinant protein production processes
44. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
45. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells
46. Simple adaptive pH control in bioreactors using gain-scheduling methods
47. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
48. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML)
49. Non-intensive treatment with low-dose 5-aza-20-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients
50. Cytogenetic Risk Features in MDS - Update and Present State: V371
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.